Merck & Co. awarded its estimated $50 million to $60 million Vioxx account to DDB
Needham Worldwide, New York. Advice & Advisors, New York, handled the non-roster shop review. The as-yet unapproved prescription drug is in a new class of pain relievers known as COX-2 inhibitors, which have no stomach side effects.
Copyright August 1998, Crain Communications Inc.